Shilpa Medicare Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

Shilpa Medicare announced that its wholly owned subsidiary, Shilpa Biocare intends to make a strategic equity partnership of 30.4% in Gate2Brain. The investment of Euro 7 million includes cash infusion of Euro 0.5 million, equity for services Euro 5.5 million and Euro 1 million for development of project.

Gate2Brain is a Barcelona-based biotechnology company developing peptide-based delivery systems that transport therapeutics across the blood-brain barrier for the treatment of central nervous system diseases. The Company is in pre-clinical stage of product development currently.

Being a strategic shareholder would allow Shilpa to participate in long-term value creation while contributing the manufacturing and regulatory depth required to bring G2B-002 to first-in-human studies and extend its application to other molecules and therapy categories.

Shilpa Medicare announced that the Board of Directors of the Company at its meeting held on 22 May 2026, inter alia, have recommended the final dividend of Rs 0.6 per equity Share (i.e. 60%) , subject to the approval of the shareholders.

Net profit of Shilpa Medicare rose 642.87% to Rs 107.79 crore in the quarter ended March 2026 as against Rs 14.51 crore during the previous quarter ended March 2025. Sales rose 32.09% to Rs 436.99 crore in the quarter ended March 2026 as against Rs 330.82 crore during the previous quarter ended March 2025.

For the full year,net profit rose 210.81% to Rs 243.33 crore in the year ended March 2026 as against Rs 78.29 crore during the previous year ended March 2025. Sales rose 19.62% to Rs 1538.87 crore in the year ended March 2026 as against Rs 1286.43 crore during the previous year ended March 2025.

Powered by Capital Market - Live News

Shilpa Medicare will hold a meeting of the Board of Directors of the Company on 22 May 2026.